Autolus Therapeutics plc (AUTL) Quick Ratio
- Quick ratio · latest quarter: Value 3.58×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 3.58× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $246.02M ÷ $68.79M ≈ 3.58× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 246.02M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 68.79M USD | Liabilities, Current |
| Cash and equivalents | 171.41M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 30.22M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 44.39M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 33.43M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $246.02M | $68.79M | $171.41M | $30.22M | $44.39M | $33.43M | 3.58× |
| 2026-03-31 | $257.10M | $63.60M | $130.93M | $98.51M | $27.66M | $33.23M | 4.04× |
| 2025-12-31 | $324.73M | $73.44M | $104.13M | $196.58M | $24.02M | $33.21M | 4.42× |
| 2025-09-30 | (m) | $83.07M | $86.12M | $281.29M | (m) | $27.72M | (m) |
| 2025-06-30 | (m) | $68.15M | $123.83M | $330.45M | (m) | $23.94M | (m) |
| 2025-03-31 | (m) | $66.61M | $95.80M | $420.78M | (m) | $14.65M | (m) |
| 2024-12-31 | $588.04M | $60.74M | $227.38M | $360.64M | $15.00K | $4.14M | 9.68× |
| 2024-09-30 | (m) | $52.47M | $657.07M | (m) | $0.00 | (m) | (m) |
| 2024-06-30 | (m) | $40.90M | $705.94M | (m) | $0.00 | (m) | (m) |
| 2024-03-31 | (m) | $43.98M | $758.53M | (m) | $0.00 | (m) | (m) |
| 2023-12-31 | (m) | $44.74M | $239.57M | (m) | $109.00K | (m) | (m) |
| 2023-09-30 | (m) | $37.54M | $256.42M | (m) | $165.00K | (m) | (m) |
| 2023-06-30 | (m) | $41.06M | $307.50M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $39.64M | $343.03M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $46.37M | $382.44M | (m) | $121.00K | (m) | (m) |
| 2022-09-30 | (m) | (m) | $163.05M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $35.52M | $216.44M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $28.84M | $268.56M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $28.55M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $30.60M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $33.63M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $30.81M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $27.27M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $26.05M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $24.98M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $20.56M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $22.30M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $21.08M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $17.14M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $5.03M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |